Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 71

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 71
---
 issue and sell to the investors, in a private placement offering, 1,212,122 Preferred Shares
with a conversion price of $1.65 per share, as well as warrants to purchase 787,880 Common Shares at an exercise price of $1.80 per share,
for aggregate gross proceeds of $2 million (the “March 2025 Offering”). The March 2025 Offering initially closed on March 28,
2025. Pursuant to the terms of the March 2025 SPA, the investors may purchase up to $1 million of additional Preferred Shares on
identical terms as the initial closing, subject to the Company obtaining shareholder approval.

On June 26, 2025, we
executed an amendment to the March 2025 SPA (the “Amendment to March 2025 SPA”). Pursuant to the terms of the Amendment to
March 2025 SPA, the investors agreed to purchase preferred participation certificates (“PPCs”) in lieu of Preferred Shares
with the same rights and privileges as the Preferred Shares. Pursuant to the terms of the Amendment to March 2025 SPA, the Company agreed
to issue 568,278 PPCs and 37,783 Preferred Shares, as well as warrants to purchase 393,939 Common Shares at an exercise price of $1.80
per share, for aggregate gross proceeds of $1 million. The second closing occurred on June 27, 2025.

In addition, on June 26,
2025, we and the Selling Shareholder entered into a side letter pursuant to which the Company agreed to issue the Selling Shareholder,
pre-funded warrants to purchase 485,000 Common Shares in lieu of our prior agreement, contained in the March 2025 SPA, to issue the Selling
Shareholder, 435,000 Preferred Shares (or their equivalent) to compensate it for certain price protection issuances and registration obligations.

The initial and second closings
of the March 2025 Offering resulted in aggregate gross proceeds to the Company of $3 million. The Company intends to use the net
proceeds from the March 2025 Offering for working capital and general corporate purposes, including for expenses relating to the Merger.

Further, on March 31,
2025, we entered into a purchase agreement with the Selling Shareholder, relating to a committed equity facility (the “ELOC Purchase
Agreement”). Pursuant to the ELOC Purchase Agreement, the Company has the right from time-to-time at its option to